

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司
AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)

(Stock code: 286)

ADDITIONAL RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcements of the Company dated 13 March 2025, 18 March 2025, 2 April 2025, 2 July 2025, 4 July 2025, 20 January 2026, 26 January 2026 and 20 May 2026 respectively (collectively, the “**Announcements**”) in relation to, among others, the guidance for the resumption of trading in the shares of the Company (the “**Shares**”) set by the Stock Exchange on 12 March 2025 (the “**Initial Resumption Guidance**”) and the resignation of Mr. Wang Bin as an independent non-executive director (“**INED**”) of the Company. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as those defined in the Announcements.

ADDITIONAL RESUMPTION GUIDANCE

As disclosed in the Company's announcement dated 20 May 2026, following the resignation of Mr. Wang Bin as an INED with effect from 20 May 2026, the Company is not in compliance with the requirements of:

- a) having the remuneration committee chaired by an INED and comprising a majority of INEDs as required under Rule 3.25; and
- b) having the nomination committee chaired by the chairman of the board or an INED and comprising a majority of INEDs as required under Rule 3.27A.

On 22 May 2026, the Company received a letter from the Stock Exchange setting out additional guidance for the resumption of trading in the Shares on the Stock Exchange (the **"Additional Resumption Guidance"**, together with the Initial Resumption Guidance, the **"Resumption Guidance"**):

- re-comply with Rules 3.10(1), 3.10A, 3.21, 3.25 and 3.27A and 13.92(2) of the Listing Rules.

The Stock Exchange also indicated that it may modify the Resumption Guidance and/or give further guidance as and when appropriate.

The Company will make further announcement(s) in relation to the above matters as and when appropriate and in accordance with the requirements of the Listing Rules to keep the Shareholders and the Company's potential investors informed of the latest progress in complying with the Resumption Guidance.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
Aidigong Maternal & Child Health Limited
Tam Mei Chu
Company Secretary

Hong Kong, 27 May 2026

As at the date of this announcement, the Board comprises Mr. Huang Wenhua and Mr. Li Runping as executive Directors; and Mr. Ma Siu Kit as independent non-executive Director.